The Most Up-to Date Microsoft070-411Exam Questions 700-505 700-501 648-232 640-911 070-462 3I0-012 070-463 Latest117-202Questions - LPIC Level 2 117-202 Certification RCDD-001 070-685 200-101 070-412 Download Cisco400-101Exams - Free VCE Exams For All 70-243 200-120 100-105 Latest 117-201 Questions - LPIC Level 2 117-201Certification C9530-404 070-480 70-487 300-207 4A0-100 600-199 350-018 070-410 100-101 CCNP Routing and Switching SWITCH300-115Official Cert M70-201 C2020-703 070-347 70-412 70-417 JN0-643 E20-690 70-410 642-747 70-331 70-413 Pass MICROSOFT70-411exam - test questions 352-001 210-260 SY0-401 200-125 300-320 200-310 CISSP PMP 300-075 210-065 Cisco CCNA Collaboration210-060CICD: Welcome to Cisco 70-534 70-532 EX200 1Z0-803 210-451 300-101 Latest HP0-S42 Questions - ASEHP0-S42Certification 300-206 070-346 70-461 HP0-S41 640-916 CompTIA Network+N10-006 EX300 1Z0-434 1Z0-060 C_HANAIMP151 C_TAW12_740 AWS-SYSOPS 70-346 2V0-620 300-070 C_HANATEC151 LatestE05-001Questions - Cloud Architect (EMCCA) JN0-360 2V0-641 642-999 70-697 300-208 FC0-U51 Latest PW0-071 Questions - CWTS PW0-071Certification C_GRCAC_10 IIA-CIA-PART3 642-732 500-260 C_HANAIMP142 98-366 1Z0-047 70-496Microsoft Real Exam Questions - 100% Free VCE Files 70-533 810-403 642-998 70-470 JN0-343 CCNP Wireless642-742New Updated Cisco 642-742 Study 220-802 70-486 642-035 JN0-692 1Z0-470 CAS-002 Cisco 642-883 Dumps |642-883Exam Questions PGMP 200-105 1Z0-051 642-887 070-688 156-215.77 400-351 H12-211Exam Huawei H12-211 Test Questions PDF C2090-930 102-400 70-696 SK0-004 101-400 1Z0-061 ADM-211 300-360 CCNP Data Center642-996Latest Version Cisco 642-996 With New 400-051 70-646 4A0-107 1Z0-574 74-343 700-039 1Z0-435Oracle Business Process Management Suite 1Y0-401 1Y0-201 200-355 74-344 300-135 Download300-370Exam PDF Questions Answers 712-50 070-496 C2090-311 300-080 640-875 AX0-100Axis Communications Real Exam Questions

General News

by Sophiris Admin

In: General News, News, Press Releases

No comments

SAN DIEGO & VANCOUVER, British Columbia –(BUSINESS WIRE)– Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational highlights for the three months and full year ended December 31, 2013.

Key Operational Highlights

  • On October 28, 2013 , the Company announced that enrollment had begun and the first patients had been dosed in a Phase 3 clinical trial of PRX302 (topsalysin) as a treatment for lower urinary tract symptoms of BPH. The Phase 3 international, multi-center trial, called the PLUS 1 study, will enroll approximately 440 patients. The randomized, double-blind and vehicle-controlled trial will assess the safety and efficacy of a single intraprostatic treatment of PRX302 (0.6 µg/g prostate). The primary endpoint is the International Prostate Symptom Score (IPSS) total score change from baseline over 52 weeks. Secondary endpoints include Qmax (maximum urine flow rate) change from baseline over 52 weeks.
  • On July 16, 2013 , the Company received a formal waiver from the Food and Drug Administration that the Company will not be required to complete a separate thorough QT study as part of our clinical development plan.
  • On August 23, 2013 , the Company announced that it had closed its initial U.S. public offering. Under the offering, the Company issued 13,000,000 common shares at a price of $5.00 per share for aggregate gross proceeds of $65 million . Following the U.S. public offering, the Company decided to voluntarily delist from the Toronto Stock Exchange , which was effective in November 2013 .
  • During the first quarter of 2013, the Company recognized revenue of $5.0 million associated with a non-refundable milestone payment due upon the achievement of certain development activities due in connection with its licensing agreement for PRX302 with Kissei Pharmaceutical Co., Ltd. The Company received payment for this milestone in April 2013 .

“2013 was an important year for positioning Sophiris to access the capital required to further the clinical development of PRX302 as a treatment for the symptoms of BPH,” stated Randall Woods , president and CEO of Sophiris Bio . “After raising $65 million in an initial U.S. public offering in August 2013 , we quickly executed on our plan for creating shareholder value by initiating our first Phase 3 clinical trial of PRX302. We believe that we are on-track to complete enrollment in the second half of 2014.”

Financial Results

At December 31, 2013 , Sophiris had cash, cash equivalents and securities available-for-sale of $48.1 million and working capital of $41.3 million . The Company expects that current cash, cash equivalents and securities available-for-sale as of December 31, 2013 will be sufficient to fund operations for at least the next 12 months.

For the Fourth Quarter Ended December 31, 2013

The Company reported a net loss of $5.4 million ( $0.34 per share) for the three months ended December 31, 2013 compared to a net loss of $5.3 million ( $1.69 per share) for the three months ended December 31, 2012 .

Research and development expenses

Research and development expenses were $4.1 million for the three months ended December 31, 2013 compared to $3.3 million for the three months ended December 31, 2012 . The increase in research and development costs was attributable to an increase in the costs associated with the Company’s first Phase 3 clinical trial and an increase in personnel costs.

General and administrative expenses

General and administrative expenses were $1 .5 million for the three months ended December 31, 2013 compared to $1 .3 million for the three months ended December 31, 2012 . This increase was due to an increase in personnel costs, an increase in stock-compensation expense and an increase in directors and officers liability insurance. These increases were offset by decreases in accounting and tax professional fees.

Interest income (expense), net

Interest expense, net was $0.2 million for the three months ended December 31, 2013 compared to $0.4 million in the same period in 2012. This decrease was due to a reduction in interest expense related to the Company’s promissory notes with Oxford Finance .

Gain on revaluation of warrant liability

Gain on revaluation of warrant liability was $0.5 million for the three months ended December 31, 2013 . The Company recognized a $0.5 million non-cash gain for the change in the fair value of the Company’s warrant liability.

Other income (expense), net

Other expense, net was $49,000 for the three months ended December 31, 2013 compared to $0.2 million for the three months ended December 31, 2012 . These amounts primarily relate to foreign exchange losses from foreign currency transactions.

For the Year Ended December 31, 2013

The Company reported a net loss of $11.1 million ( $1.39 per share) for the year ended December 31, 2013 compared to a net loss of $21.2 million ( $6.94 per share) for the year ended December 31, 2012 .

License revenue

During the year ended December 31, 2013 , the Company recorded as revenue a $5 .0 million non-refundable milestone payment due from Kissei upon its achievement of certain development activities.

Research and development expenses

Research and development expenses were $10.3 million in the year ended December 31, 2013 compared to $13.5 million in the year ended December 31, 2012 . The decrease in research and development costs was attributable to a decrease in the costs associated with the Company’s non-clinical activities, specifically a repeat dose monkey study and a rat fertility study both of which were completed in 2012, a decrease in the costs associated with the transfer and scale-up of manufacturing activities for PRX302, and a decrease in costs associated with the Company’s completed Phase 1/2 transrectal clinical trial. Offsetting these decreases was an increase in costs associated with the Company’s first Phase 3 clinical trial.

General and administrative expenses

General and administrative expenses were $4.5 million in the year ended December 31, 2013 compared to $5.7 million for the year ended December 31, 2012 . The decrease was primarily due to a decrease in market research costs.

Interest income (expense), net

Interest expense, net was $1.3 million in the year ended December 31, 2013 , compared to $1.9 million in the same period in 2012. This decrease was due to a reduction in interest expense related to the Company’s promissory notes with Oxford Finance .

Gain on revaluation of warrant liability

Gain on revaluation of warrant liability was $0.7 million as of December 31, 2013 . The non-cash gain was associated with the change in the fair value of the Company’s warrant liability.

Other income (expense), net

Other expense, net was $0.2 million for the year ended December 31, 2013 compared to $0.1 million for the year ended December 31, 2012 . These amounts primarily relate to foreign exchange losses from foreign currency transactions.

Income tax expense

The milestone payment from Kissei was subject to a 10 percent Japanese withholding tax. As a result the Company recorded an income tax expense of $0.5 million for the year ended December 31, 2013 .

For complete financial results, please see the Company’s website at www.sophiris.com.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of BPH, which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris initiated its first Phase 3 clinical trial of PRX302 in October 2013 . For more information, please visit www.sophiris.com.

Certain statements included in this press release may be considered forward-looking, including the quote of our President and CEO and any expectations relating to our Phase 3 trial of PRX302 or our capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, clinical trial enrollment and results, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Balance Sheets

(in thousands, except share amounts)

(unaudited)

December 31 ,
2013 2012
Assets:
Current assets:
Cash and cash equivalents

$

14,839

$

9,721

Securities available-for-sale 33,310
Other receivables 48 71
Deferred financing costs 937
Prepaid expenses 3,598 593
Total current assets 51,795 11,322
Property and equipment, net 78 163
Other long-term assets 19 44
Total assets

$

51,892

$

11,529

Liabilities and shareholders’ equity (deficit):
Current liabilities:
Accounts payable

$

1,470

$

1,774

Accrued expenses 2,181 2,839
Current portion of promissory notes 6,877 5,895
Total current liabilities 10,528 10,508
Long-term promissory notes, less current portion 6,126
Warrant liability 883
Stock-based compensation liability 202
Total liabilities 11,613 16,634
Commitments and contingencies
Shareholders’ equity (deficit):

Common shares, unlimited authorized shares, no par value; 16,149,871 and 3,149,871
shares issued and outstanding at December 31, 2013 and 2012, respectively

111,204 54,215
Common share purchase warrants 6,045
Contributed surplus 13,824 8,379
Accumulated other comprehensive (loss) gain 98 (46 )
Deficit accumulated during development stage (84,847 ) (73,698 )
Total shareholders’ equity (deficit) 40,279 (5,105 )
Total liabilities and shareholders’ equity (deficit)

$

51,892

$

11,529

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Statement of Operations and Comprehensive Loss

(in thousands, expect per share amounts)

(unaudited)

Three Months Ended

December 31 ,

Year Ended

December 31 ,

Cumulative
period
from
January
11, 2002
(date of
inception) to
December
31,

2013 2012 2013 2012 2013
Revenues:
License revenue

$

$

$

5,000

$

$

8,000

Operating expenses:
Research and development 4,136 3,329 10,279 13,523 59,924
General and administrative 1,502 1,343 4,511 5,685 28,989
Total operating expenses 5,638 4,672 14,790 19,208 88,913
Other income (expense):
Interest income (expense), net (244 ) (430 ) (1,308 ) (1,880 ) (3,221 )
Gain on revaluation of warrant liability 493 689

689

Other income (expense), net (49 ) (228 ) (240 ) (106 ) (587 )
Total other income (expense) 200 (658 ) (859 ) (1,986 ) (3,119 )
Net loss before income taxes (5,438 ) (5,330 ) (10,649 ) (21,194 ) (84,032 )
Income tax expense (500 ) (815 )
Net loss

$

(5,438

)

$

(5,330

)

$

(11,149

)

(21,194 )

$

(84,847

)

Basic and diluted loss per share

$

(0.34

)

$

(1.69

)

$

(1.39

)

$

(6.94

)

Weighted average number of outstanding shares – basic and diluted 16,150 3,150 8,029 3,054

Other comprehensive income (loss)

Foreign currency translation adjustment

23 145 131 99
Unrealized loss on securities available-for sale (1 ) (1 ) (1 )
Total comprehensive loss

$

(5,439

)

$

(5,307

)

$

(11,005

)

$

(21,063

)

$

(84,749

)

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Statement of Cash Flows

(in thousands)

(unaudited)

Year Ended

December 31 ,

 

Cumulative Period
From January 11 ,
2002 (date of
inception) to
December 31 ,

    2013 2012 2013Cash flows used in operating activities         Net loss for the period   $(11,149 ) $(21,194) $(84,847)Adjustments to reconcile net loss to net cash used by operating activities:         Stock-based compensation   1,174   676  5,511 Accretion of debt discount   380   509  1,110 Depreciation of property and equipment   84   82  607 Amortization of intangible assets   —   149  1,205 Amortization of promissory note issuance costs   108   155  331 Amortization of discount on available-for-sale securities   9   —  9 Impairment loss   —   176  176 Change in fair value warrant liability   (689)  —  (689)Foreign exchange transaction (gain) loss   229   (148) (1,438)Loss on disposal of assets   2   1  27 Other   —   —  182 Changes in operating assets and liabilities:         Other receivables   23   172  9 Prepaid expenses   (3,112)  (162) (3,916)Other long-term assets   25   (15) (19)Accounts payable   (305)  (1,006) 984 Accrued expenses   15   1,769  2,333 Net cash used in operating activities   (13,206)  (18,836) (78,425)          Cash flows used in investing activities         Purchases of property and equipment   (3)  (26) (725)Proceeds from the disposal of property and equipment   1   —  13 Acquisition of intangible assets   —   —  (1,372)Maturity of marketable securities   —   —  1,112 Purchases of securities available-for-sale   (33,320)  —  (34,433)Net cash used in investing activities   (33,322)  (26) (35,405)          Cash flows from financing activities         Issuance of common shares from private placement, net of issuance cost   —   8,285  50,179 Issuance of common shares from public offering, net of issuance cost   57,253   (211) 60,070 Issuance of preferred shares, net of issuance cost   —   —  465 Cash acquired on reverse acquisition   —   —  818 Issuance of common shares on exercise of warrants   —   —  8,702 Issuance of common shares on exercise of stock options   —   —  514 Cash received from the issuance of promissory notes   —   —  15,000 Principal payments on notes payable   (5,524)  (3,190) (8,714)Increase in lease obligations   —   —  120 Capital lease payments   —   —  (120)Other   —   —  4 Net cash provided by financing activities   51,729   4,884  127,038 Effect of exchange rate changes on cash and cash equivalents   (83)  289  1,631 Net increase (decrease) in cash and cash equivalents   5,118   (13,689) 14,839 Cash and cash equivalents at beginning of period   9,721   23,410  — Cash and cash equivalents at end of period   $14,839   $9,721  $14,839

Sophiris Bio Inc.
Peter Slover , 858-777-1760
Chief Financial Officer
or
Canale Communications
Jason Spark , 619-849-6005
Corporate Communications and IR
jason@canalecomm.com
or
Equicom Group
Michael Moore , 858-886-7813
Investor Relations
mmoore@tmxequicom.com

News Provided by Acquire Media

SAN DIEGO & VANCOUVER, British Columbia –(BUSINESS WIRE)– Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational highlights for the three months and full year ended December 31, 2013.

Key Operational Highlights

  • On October 28, 2013 , the Company announced that enrollment had begun and the first patients had been dosed in a Phase 3 clinical trial of PRX302 (topsalysin) as a treatment for lower urinary tract symptoms of BPH. The Phase 3 international, multi-center trial, called the PLUS 1 study, will enroll approximately 440 patients. The randomized, double-blind and vehicle-controlled trial will assess the safety and efficacy of a single intraprostatic treatment of PRX302 (0.6 µg/g prostate). The primary endpoint is the International Prostate Symptom Score (IPSS) total score change from baseline over 52 weeks. Secondary endpoints include Qmax (maximum urine flow rate) change from baseline over 52 weeks.
  • On July 16, 2013 , the Company received a formal waiver from the Food and Drug Administration that the Company will not be required to complete a separate thorough QT study as part of our clinical development plan.
  • On August 23, 2013 , the Company announced that it had closed its initial U.S. public offering. Under the offering, the Company issued 13,000,000 common shares at a price of $5.00 per share for aggregate gross proceeds of $65 million . Following the U.S. public offering, the Company decided to voluntarily delist from the Toronto Stock Exchange , which was effective in November 2013 .
  • During the first quarter of 2013, the Company recognized revenue of $5.0 million associated with a non-refundable milestone payment due upon the achievement of certain development activities due in connection with its licensing agreement for PRX302 with Kissei Pharmaceutical Co., Ltd. The Company received payment for this milestone in April 2013 .

“2013 was an important year for positioning Sophiris to access the capital required to further the clinical development of PRX302 as a treatment for the symptoms of BPH,” stated Randall Woods , president and CEO of Sophiris Bio . “After raising $65 million in an initial U.S. public offering in August 2013 , we quickly executed on our plan for creating shareholder value by initiating our first Phase 3 clinical trial of PRX302. We believe that we are on-track to complete enrollment in the second half of 2014.”

Financial Results

At December 31, 2013 , Sophiris had cash, cash equivalents and securities available-for-sale of $48.1 million and working capital of $41.3 million . The Company expects that current cash, cash equivalents and securities available-for-sale as of December 31, 2013 will be sufficient to fund operations for at least the next 12 months.

For the Fourth Quarter Ended December 31, 2013

The Company reported a net loss of $5.4 million ( $0.34 per share) for the three months ended December 31, 2013 compared to a net loss of $5.3 million ( $1.69 per share) for the three months ended December 31, 2012 .

Research and development expenses

Research and development expenses were $4.1 million for the three months ended December 31, 2013 compared to $3.3 million for the three months ended December 31, 2012 . The increase in research and development costs was attributable to an increase in the costs associated with the Company’s first Phase 3 clinical trial and an increase in personnel costs.

General and administrative expenses

General and administrative expenses were $1 .5 million for the three months ended December 31, 2013 compared to $1 .3 million for the three months ended December 31, 2012 . This increase was due to an increase in personnel costs, an increase in stock-compensation expense and an increase in directors and officers liability insurance. These increases were offset by decreases in accounting and tax professional fees.

Interest income (expense), net

Interest expense, net was $0.2 million for the three months ended December 31, 2013 compared to $0.4 million in the same period in 2012. This decrease was due to a reduction in interest expense related to the Company’s promissory notes with Oxford Finance .

Gain on revaluation of warrant liability

Gain on revaluation of warrant liability was $0.5 million for the three months ended December 31, 2013 . The Company recognized a $0.5 million non-cash gain for the change in the fair value of the Company’s warrant liability.

Other income (expense), net

Other expense, net was $49,000 for the three months ended December 31, 2013 compared to $0.2 million for the three months ended December 31, 2012 . These amounts primarily relate to foreign exchange losses from foreign currency transactions.

For the Year Ended December 31, 2013

The Company reported a net loss of $11.1 million ( $1.39 per share) for the year ended December 31, 2013 compared to a net loss of $21.2 million ( $6.94 per share) for the year ended December 31, 2012 .

License revenue

During the year ended December 31, 2013 , the Company recorded as revenue a $5 .0 million non-refundable milestone payment due from Kissei upon its achievement of certain development activities.

Research and development expenses

Research and development expenses were $10.3 million in the year ended December 31, 2013 compared to $13.5 million in the year ended December 31, 2012 . The decrease in research and development costs was attributable to a decrease in the costs associated with the Company’s non-clinical activities, specifically a repeat dose monkey study and a rat fertility study both of which were completed in 2012, a decrease in the costs associated with the transfer and scale-up of manufacturing activities for PRX302, and a decrease in costs associated with the Company’s completed Phase 1/2 transrectal clinical trial. Offsetting these decreases was an increase in costs associated with the Company’s first Phase 3 clinical trial.

General and administrative expenses

General and administrative expenses were $4.5 million in the year ended December 31, 2013 compared to $5.7 million for the year ended December 31, 2012 . The decrease was primarily due to a decrease in market research costs.

Interest income (expense), net

Interest expense, net was $1.3 million in the year ended December 31, 2013 , compared to $1.9 million in the same period in 2012. This decrease was due to a reduction in interest expense related to the Company’s promissory notes with Oxford Finance .

Gain on revaluation of warrant liability

Gain on revaluation of warrant liability was $0.7 million as of December 31, 2013 . The non-cash gain was associated with the change in the fair value of the Company’s warrant liability.

Other income (expense), net

Other expense, net was $0.2 million for the year ended December 31, 2013 compared to $0.1 million for the year ended December 31, 2012 . These amounts primarily relate to foreign exchange losses from foreign currency transactions.

Income tax expense

The milestone payment from Kissei was subject to a 10 percent Japanese withholding tax. As a result the Company recorded an income tax expense of $0.5 million for the year ended December 31, 2013 .

For complete financial results, please see the Company’s website at www.sophiris.com.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of BPH, which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris initiated its first Phase 3 clinical trial of PRX302 in October 2013 . For more information, please visit www.sophiris.com.

Certain statements included in this press release may be considered forward-looking, including the quote of our President and CEO and any expectations relating to our Phase 3 trial of PRX302 or our capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, clinical trial enrollment and results, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Balance Sheets

(in thousands, except share amounts)

(unaudited)

December 31 ,
2013 2012
Assets:
Current assets:
Cash and cash equivalents

$

14,839

$

9,721

Securities available-for-sale 33,310
Other receivables 48 71
Deferred financing costs 937
Prepaid expenses 3,598 593
Total current assets 51,795 11,322
Property and equipment, net 78 163
Other long-term assets 19 44
Total assets

$

51,892

$

11,529

Liabilities and shareholders’ equity (deficit):
Current liabilities:
Accounts payable

$

1,470

$

1,774

Accrued expenses 2,181 2,839
Current portion of promissory notes 6,877 5,895
Total current liabilities 10,528 10,508
Long-term promissory notes, less current portion 6,126
Warrant liability 883
Stock-based compensation liability 202
Total liabilities 11,613 16,634
Commitments and contingencies
Shareholders’ equity (deficit):

Common shares, unlimited authorized shares, no par value; 16,149,871 and 3,149,871
shares issued and outstanding at December 31, 2013 and 2012, respectively

111,204 54,215
Common share purchase warrants 6,045
Contributed surplus 13,824 8,379
Accumulated other comprehensive (loss) gain 98 (46 )
Deficit accumulated during development stage (84,847 ) (73,698 )
Total shareholders’ equity (deficit) 40,279 (5,105 )
Total liabilities and shareholders’ equity (deficit)

$

51,892

$

11,529

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Statement of Operations and Comprehensive Loss

(in thousands, expect per share amounts)

(unaudited)

Three Months Ended

December 31 ,

Year Ended

December 31 ,

Cumulative
period
from
January
11, 2002
(date of
inception) to
December
31,

2013 2012 2013 2012 2013
Revenues:
License revenue

$

$

$

5,000

$

$

8,000

Operating expenses:
Research and development 4,136 3,329 10,279 13,523 59,924
General and administrative 1,502 1,343 4,511 5,685 28,989
Total operating expenses 5,638 4,672 14,790 19,208 88,913
Other income (expense):
Interest income (expense), net (244 ) (430 ) (1,308 ) (1,880 ) (3,221 )
Gain on revaluation of warrant liability 493 689

689

Other income (expense), net (49 ) (228 ) (240 ) (106 ) (587 )
Total other income (expense) 200 (658 ) (859 ) (1,986 ) (3,119 )
Net loss before income taxes (5,438 ) (5,330 ) (10,649 ) (21,194 ) (84,032 )
Income tax expense (500 ) (815 )
Net loss

$

(5,438

)

$

(5,330

)

$

(11,149

)

(21,194 )

$

(84,847

)

Basic and diluted loss per share

$

(0.34

)

$

(1.69

)

$

(1.39

)

$

(6.94

)

Weighted average number of outstanding shares – basic and diluted 16,150 3,150 8,029 3,054

Other comprehensive income (loss)

Foreign currency translation adjustment

23 145 131 99
Unrealized loss on securities available-for sale (1 ) (1 ) (1 )
Total comprehensive loss

$

(5,439

)

$

(5,307

)

$

(11,005

)

$

(21,063

)

$

(84,749

)

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Statement of Cash Flows

(in thousands)

(unaudited)

Year Ended

December 31 ,

 

Cumulative Period
From January 11 ,
2002 (date of
inception) to
December 31 ,

    2013 2012 2013Cash flows used in operating activities         Net loss for the period   $(11,149 ) $(21,194) $(84,847)Adjustments to reconcile net loss to net cash used by operating activities:         Stock-based compensation   1,174   676  5,511 Accretion of debt discount   380   509  1,110 Depreciation of property and equipment   84   82  607 Amortization of intangible assets   —   149  1,205 Amortization of promissory note issuance costs   108   155  331 Amortization of discount on available-for-sale securities   9   —  9 Impairment loss   —   176  176 Change in fair value warrant liability   (689)  —  (689)Foreign exchange transaction (gain) loss   229   (148) (1,438)Loss on disposal of assets   2   1  27 Other   —   —  182 Changes in operating assets and liabilities:         Other receivables   23   172  9 Prepaid expenses   (3,112)  (162) (3,916)Other long-term assets   25   (15) (19)Accounts payable   (305)  (1,006) 984 Accrued expenses   15   1,769  2,333 Net cash used in operating activities   (13,206)  (18,836) (78,425)          Cash flows used in investing activities         Purchases of property and equipment   (3)  (26) (725)Proceeds from the disposal of property and equipment   1   —  13 Acquisition of intangible assets   —   —  (1,372)Maturity of marketable securities   —   —  1,112 Purchases of securities available-for-sale   (33,320)  —  (34,433)Net cash used in investing activities   (33,322)  (26) (35,405)          Cash flows from financing activities         Issuance of common shares from private placement, net of issuance cost   —   8,285  50,179 Issuance of common shares from public offering, net of issuance cost   57,253   (211) 60,070 Issuance of preferred shares, net of issuance cost   —   —  465 Cash acquired on reverse acquisition   —   —  818 Issuance of common shares on exercise of warrants   —   —  8,702 Issuance of common shares on exercise of stock options   —   —  514 Cash received from the issuance of promissory notes   —   —  15,000 Principal payments on notes payable   (5,524)  (3,190) (8,714)Increase in lease obligations   —   —  120 Capital lease payments   —   —  (120)Other   —   —  4 Net cash provided by financing activities   51,729   4,884  127,038 Effect of exchange rate changes on cash and cash equivalents   (83)  289  1,631 Net increase (decrease) in cash and cash equivalents   5,118   (13,689) 14,839 Cash and cash equivalents at beginning of period   9,721   23,410  — Cash and cash equivalents at end of period   $14,839   $9,721  $14,839

Sophiris Bio Inc.
Peter Slover , 858-777-1760
Chief Financial Officer
or
Canale Communications
Jason Spark , 619-849-6005
Corporate Communications and IR
jason@canalecomm.com
or
Equicom Group
Michael Moore , 858-886-7813
Investor Relations
mmoore@tmxequicom.com

News Provided by Acquire Media

SAN DIEGO & VANCOUVER, British Columbia –(BUSINESS WIRE)– Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational highlights for the three months and full year ended December 31, 2013.

Key Operational Highlights

  • On October 28, 2013 , the Company announced that enrollment had begun and the first patients had been dosed in a Phase 3 clinical trial of PRX302 (topsalysin) as a treatment for lower urinary tract symptoms of BPH. The Phase 3 international, multi-center trial, called the PLUS 1 study, will enroll approximately 440 patients. The randomized, double-blind and vehicle-controlled trial will assess the safety and efficacy of a single intraprostatic treatment of PRX302 (0.6 µg/g prostate). The primary endpoint is the International Prostate Symptom Score (IPSS) total score change from baseline over 52 weeks. Secondary endpoints include Qmax (maximum urine flow rate) change from baseline over 52 weeks.
  • On July 16, 2013 , the Company received a formal waiver from the Food and Drug Administration that the Company will not be required to complete a separate thorough QT study as part of our clinical development plan.
  • On August 23, 2013 , the Company announced that it had closed its initial U.S. public offering. Under the offering, the Company issued 13,000,000 common shares at a price of $5.00 per share for aggregate gross proceeds of $65 million . Following the U.S. public offering, the Company decided to voluntarily delist from the Toronto Stock Exchange , which was effective in November 2013 .
  • During the first quarter of 2013, the Company recognized revenue of $5.0 million associated with a non-refundable milestone payment due upon the achievement of certain development activities due in connection with its licensing agreement for PRX302 with Kissei Pharmaceutical Co., Ltd. The Company received payment for this milestone in April 2013 .

“2013 was an important year for positioning Sophiris to access the capital required to further the clinical development of PRX302 as a treatment for the symptoms of BPH,” stated Randall Woods , president and CEO of Sophiris Bio . “After raising $65 million in an initial U.S. public offering in August 2013 , we quickly executed on our plan for creating shareholder value by initiating our first Phase 3 clinical trial of PRX302. We believe that we are on-track to complete enrollment in the second half of 2014.”

Financial Results

At December 31, 2013 , Sophiris had cash, cash equivalents and securities available-for-sale of $48.1 million and working capital of $41.3 million . The Company expects that current cash, cash equivalents and securities available-for-sale as of December 31, 2013 will be sufficient to fund operations for at least the next 12 months.

For the Fourth Quarter Ended December 31, 2013

The Company reported a net loss of $5.4 million ( $0.34 per share) for the three months ended December 31, 2013 compared to a net loss of $5.3 million ( $1.69 per share) for the three months ended December 31, 2012 .

Research and development expenses

Research and development expenses were $4.1 million for the three months ended December 31, 2013 compared to $3.3 million for the three months ended December 31, 2012 . The increase in research and development costs was attributable to an increase in the costs associated with the Company’s first Phase 3 clinical trial and an increase in personnel costs.

General and administrative expenses

General and administrative expenses were $1 .5 million for the three months ended December 31, 2013 compared to $1 .3 million for the three months ended December 31, 2012 . This increase was due to an increase in personnel costs, an increase in stock-compensation expense and an increase in directors and officers liability insurance. These increases were offset by decreases in accounting and tax professional fees.

Interest income (expense), net

Interest expense, net was $0.2 million for the three months ended December 31, 2013 compared to $0.4 million in the same period in 2012. This decrease was due to a reduction in interest expense related to the Company’s promissory notes with Oxford Finance .

Gain on revaluation of warrant liability

Gain on revaluation of warrant liability was $0.5 million for the three months ended December 31, 2013 . The Company recognized a $0.5 million non-cash gain for the change in the fair value of the Company’s warrant liability.

Other income (expense), net

Other expense, net was $49,000 for the three months ended December 31, 2013 compared to $0.2 million for the three months ended December 31, 2012 . These amounts primarily relate to foreign exchange losses from foreign currency transactions.

For the Year Ended December 31, 2013

The Company reported a net loss of $11.1 million ( $1.39 per share) for the year ended December 31, 2013 compared to a net loss of $21.2 million ( $6.94 per share) for the year ended December 31, 2012 .

License revenue

During the year ended December 31, 2013 , the Company recorded as revenue a $5 .0 million non-refundable milestone payment due from Kissei upon its achievement of certain development activities.

Research and development expenses

Research and development expenses were $10.3 million in the year ended December 31, 2013 compared to $13.5 million in the year ended December 31, 2012 . The decrease in research and development costs was attributable to a decrease in the costs associated with the Company’s non-clinical activities, specifically a repeat dose monkey study and a rat fertility study both of which were completed in 2012, a decrease in the costs associated with the transfer and scale-up of manufacturing activities for PRX302, and a decrease in costs associated with the Company’s completed Phase 1/2 transrectal clinical trial. Offsetting these decreases was an increase in costs associated with the Company’s first Phase 3 clinical trial.

General and administrative expenses

General and administrative expenses were $4.5 million in the year ended December 31, 2013 compared to $5.7 million for the year ended December 31, 2012 . The decrease was primarily due to a decrease in market research costs.

Interest income (expense), net

Interest expense, net was $1.3 million in the year ended December 31, 2013 , compared to $1.9 million in the same period in 2012. This decrease was due to a reduction in interest expense related to the Company’s promissory notes with Oxford Finance .

Gain on revaluation of warrant liability

Gain on revaluation of warrant liability was $0.7 million as of December 31, 2013 . The non-cash gain was associated with the change in the fair value of the Company’s warrant liability.

Other income (expense), net

Other expense, net was $0.2 million for the year ended December 31, 2013 compared to $0.1 million for the year ended December 31, 2012 . These amounts primarily relate to foreign exchange losses from foreign currency transactions.

Income tax expense

The milestone payment from Kissei was subject to a 10 percent Japanese withholding tax. As a result the Company recorded an income tax expense of $0.5 million for the year ended December 31, 2013 .

For complete financial results, please see the Company’s website at www.sophiris.com.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of BPH, which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris initiated its first Phase 3 clinical trial of PRX302 in October 2013 . For more information, please visit www.sophiris.com.

Certain statements included in this press release may be considered forward-looking, including the quote of our President and CEO and any expectations relating to our Phase 3 trial of PRX302 or our capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, clinical trial enrollment and results, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Balance Sheets

(in thousands, except share amounts)

(unaudited)

December 31 ,
2013 2012
Assets:
Current assets:
Cash and cash equivalents

$

14,839

$

9,721

Securities available-for-sale 33,310
Other receivables 48 71
Deferred financing costs 937
Prepaid expenses 3,598 593
Total current assets 51,795 11,322
Property and equipment, net 78 163
Other long-term assets 19 44
Total assets

$

51,892

$

11,529

Liabilities and shareholders’ equity (deficit):
Current liabilities:
Accounts payable

$

1,470

$

1,774

Accrued expenses 2,181 2,839
Current portion of promissory notes 6,877 5,895
Total current liabilities 10,528 10,508
Long-term promissory notes, less current portion 6,126
Warrant liability 883
Stock-based compensation liability 202
Total liabilities 11,613 16,634
Commitments and contingencies
Shareholders’ equity (deficit):

Common shares, unlimited authorized shares, no par value; 16,149,871 and 3,149,871
shares issued and outstanding at December 31, 2013 and 2012, respectively

111,204 54,215
Common share purchase warrants 6,045
Contributed surplus 13,824 8,379
Accumulated other comprehensive (loss) gain 98 (46 )
Deficit accumulated during development stage (84,847 ) (73,698 )
Total shareholders’ equity (deficit) 40,279 (5,105 )
Total liabilities and shareholders’ equity (deficit)

$

51,892

$

11,529

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Statement of Operations and Comprehensive Loss

(in thousands, expect per share amounts)

(unaudited)

Three Months Ended

December 31 ,

Year Ended

December 31 ,

Cumulative
period
from
January
11, 2002
(date of
inception) to
December
31,

2013 2012 2013 2012 2013
Revenues:
License revenue

$

$

$

5,000

$

$

8,000

Operating expenses:
Research and development 4,136 3,329 10,279 13,523 59,924
General and administrative 1,502 1,343 4,511 5,685 28,989
Total operating expenses 5,638 4,672 14,790 19,208 88,913
Other income (expense):
Interest income (expense), net (244 ) (430 ) (1,308 ) (1,880 ) (3,221 )
Gain on revaluation of warrant liability 493 689

689

Other income (expense), net (49 ) (228 ) (240 ) (106 ) (587 )
Total other income (expense) 200 (658 ) (859 ) (1,986 ) (3,119 )
Net loss before income taxes (5,438 ) (5,330 ) (10,649 ) (21,194 ) (84,032 )
Income tax expense (500 ) (815 )
Net loss

$

(5,438

)

$

(5,330

)

$

(11,149

)

(21,194 )

$

(84,847

)

Basic and diluted loss per share

$

(0.34

)

$

(1.69

)

$

(1.39

)

$

(6.94

)

Weighted average number of outstanding shares – basic and diluted 16,150 3,150 8,029 3,054

Other comprehensive income (loss)

Foreign currency translation adjustment

23 145 131 99
Unrealized loss on securities available-for sale (1 ) (1 ) (1 )
Total comprehensive loss

$

(5,439

)

$

(5,307

)

$

(11,005

)

$

(21,063

)

$

(84,749

)

Sophiris Bio Inc.

(A Development Stage Company)

Consolidated Statement of Cash Flows

(in thousands)

(unaudited)

Year Ended

December 31 ,

 

Cumulative Period
From January 11 ,
2002 (date of
inception) to
December 31 ,

    2013 2012 2013Cash flows used in operating activities         Net loss for the period   $(11,149 ) $(21,194) $(84,847)Adjustments to reconcile net loss to net cash used by operating activities:         Stock-based compensation   1,174   676  5,511 Accretion of debt discount   380   509  1,110 Depreciation of property and equipment   84   82  607 Amortization of intangible assets   —   149  1,205 Amortization of promissory note issuance costs   108   155  331 Amortization of discount on available-for-sale securities   9   —  9 Impairment loss   —   176  176 Change in fair value warrant liability   (689)  —  (689)Foreign exchange transaction (gain) loss   229   (148) (1,438)Loss on disposal of assets   2   1  27 Other   —   —  182 Changes in operating assets and liabilities:         Other receivables   23   172  9 Prepaid expenses   (3,112)  (162) (3,916)Other long-term assets   25   (15) (19)Accounts payable   (305)  (1,006) 984 Accrued expenses   15   1,769  2,333 Net cash used in operating activities   (13,206)  (18,836) (78,425)          Cash flows used in investing activities         Purchases of property and equipment   (3)  (26) (725)Proceeds from the disposal of property and equipment   1   —  13 Acquisition of intangible assets   —   —  (1,372)Maturity of marketable securities   —   —  1,112 Purchases of securities available-for-sale   (33,320)  —  (34,433)Net cash used in investing activities   (33,322)  (26) (35,405)          Cash flows from financing activities         Issuance of common shares from private placement, net of issuance cost   —   8,285  50,179 Issuance of common shares from public offering, net of issuance cost   57,253   (211) 60,070 Issuance of preferred shares, net of issuance cost   —   —  465 Cash acquired on reverse acquisition   —   —  818 Issuance of common shares on exercise of warrants   —   —  8,702 Issuance of common shares on exercise of stock options   —   —  514 Cash received from the issuance of promissory notes   —   —  15,000 Principal payments on notes payable   (5,524)  (3,190) (8,714)Increase in lease obligations   —   —  120 Capital lease payments   —   —  (120)Other   —   —  4 Net cash provided by financing activities   51,729   4,884  127,038 Effect of exchange rate changes on cash and cash equivalents   (83)  289  1,631 Net increase (decrease) in cash and cash equivalents   5,118   (13,689) 14,839 Cash and cash equivalents at beginning of period   9,721   23,410  — Cash and cash equivalents at end of period   $14,839   $9,721  $14,839

Sophiris Bio Inc.
Peter Slover , 858-777-1760
Chief Financial Officer
or
Canale Communications
Jason Spark , 619-849-6005
Corporate Communications and IR
jason@canalecomm.com
or
Equicom Group
Michael Moore , 858-886-7813
Investor Relations
mmoore@tmxequicom.com

News Provided by Acquire Media

070-411 , 700-505 , 700-501 , 648-232 , 640-911 , 070-462 , 3I0-012 , 200-101 , C2020-703 , 070-347 , 070-463 , 070-412 , 117-202 , 400-101 , 70-412 , 70-243 , 70-417 , 200-120 , 100-105 , 117-201 , C9530-404 , 070-480 , 70-487 , 300-207 , JN0-643 , 4A0-100 , 600-199 , E20-690 , 350-018 , 070-410 , 70-410 , 100-101 , 642-747 , 70-331 , 70-413 , 70-411 , 352-001 , 210-260 , SY0-401 , 200-125 , 300-320 , 200-310 , CISSP , 300-115 , PMP , 300-075 , 210-065 , 210-060 , 70-534 , 70-532 , EX200 , 1Z0-803 , 210-451 , 300-101 , HP0-S42 , 300-206 , 070-346 , 70-461 , HP0-S41 , 640-916 , N10-006 , EX300 , 1Z0-434 , 1Z0-060 , C_HANAIMP151 , C_TAW12_740 , AWS-SYSOPS , 70-346 , 2V0-620 , 300-070 , C_HANATEC151 , E05-001 , JN0-360 , 2V0-641 , M70-201 , 642-999 , 70-697 , 300-208 , FC0-U51 , PW0-071 , C_GRCAC_10 , IIA-CIA-PART3 , 642-732 , 500-260 , C_HANAIMP142 , 98-366 , 1Z0-047 , 70-496 , 70-533 , 810-403 , 642-998 , 70-470 , JN0-343 , 642-742 , 220-802 , 70-486 , 642-035 , JN0-692 , 1Z0-470 , CAS-002 , 642-883 , PGMP , 200-105 , 1Z0-051 , 642-887 , 070-688 , 156-215.77 , RCDD-001 , 400-351 , H12-211 , C2090-930 , 102-400 , 70-696 , 070-685 , SK0-004 , 101-400 , 1Z0-061 , ADM-211 , 300-360 , 642-996 ,